During a virtual meet hosted by the Wall Street Journal, on the leading CEOs, Eric Yuan stated that at his peak he once attended 19 Zoom meetings in a row in one day.

When questioned if even he suffered from ‘Zoom fatigue’, Yuan answered, chuckling, “I’m so tired of that.”

“I do have meeting fatigue. I do not have any back-to-back meetings anymore, and I feel much more comfortable now,” the company founder stated.

Set up in 2011, Zoom, was relatively unknown before gaining worldwide presence, after the pandemic hit globally and workers across the world were forced to start working from home.

According to Forbes, Eric Yuan’s worth is $13.2 billion, which ranks him at No.133 in the list of billionaires.

However, Yuan now wished that his own staff could go back to the old-fashioned style of meetings. He stated that the Zoom staff is expected to return to the office at least two days a week.

Zoom is taking advantage of a surge in investor interest after the stock quintupled in value last year when the company’s flagship product became a household name. Zoom is already profitable, but the share sale will pad its balance sheet. As of October, the company had $730.5 million of cash and equivalents, up from $283.1 million in January.

The video chat company, which has been a major beneficiary of the remote work boom during the Covid-19 pandemic, is assuming a share price of $337.71, based on Monday’s close. Zoom went public less than two years ago, selling shares at $36 apiece.

With a market cap of close to $100 billion, Zoom has the equity to make significant acquisitions.

The secondary sale will provide the capital to combine cash and potentially make deals more attractive to targets. Zoom said it plans to use the money for operating expenses and capital expenditures, and “may also use a portion of the net proceeds for acquisitions or strategic investments in complementary businesses, products, services or technologies.”

While Zoom’s valuation has multiplied 10-fold since its IPO, the company is significantly off its high. Since peaking at $568.34 in mid-October, Zoom shares have dropped more than 41%, taking their biggest hit on reports that Covid-19 vaccines were highly effective and would be rushed to market.